checkedThe Carlat Psychiatry Podcast2026-10-26last verified 2026-10-26

did a swedish study find stimulant users had 25% higher cardiovascular risk by year five?

verdict: misattributed
a real number attached to the wrong thing
“By year five, stimulant users had a 25% increase in risk compared to those not on ADHD medications.”

a host, a psychiatrist said on The Carlat Psychiatry Podcast, 2026-10-26, at 02:04. hear it in context → the speaker cited: a Swedish study.

the episode: Balancing Focus and Cardiovascular Risk with ADHD Treatment (at 02:04). we link the show's own page; we do not re-host audio.

first, the part that holds

the swedish study exists and the number is real: people with adhd who had taken adhd medication for 3 to 5 years had about 27% higher odds of a new cardiovascular diagnosis than people with adhd who took none, and about 23% higher after more than 5 years. "about 25% by year five" is a fair rounding of those two figures.

what we found when we went and looked

we read the study: a 2024 jama psychiatry nested case-control analysis of 278,027 people with adhd aged 6 to 64 in swedish national registers, with 10,388 cardiovascular cases matched to 51,672 controls. compared with people with adhd who took no medication, the adjusted odds ratio was 1.27 (95% ci 1.17-1.39) after 3 to 5 years of cumulative use and 1.23 (1.12-1.36) after more than 5 years. the catch is that these figures cover all adhd medications combined, nonstimulants included, not stimulant users alone. for methylphenidate, the main stimulant, the study reports 1.20 at 3 to 5 years and 1.19 after 5 years. the extra risk was mostly hypertension and arterial disease. the study found no significant rise in heart attack, stroke or arrhythmia.

assertion by assertion

assertionverdictwhat the record says
a swedish study found about 25% higher cardiovascular risk by around year five of adhd medication use, compared with no adhd medicationconfirmedfor any adhd medication vs nonuse, the adjusted odds ratio was 1.27 (95% ci 1.17-1.39) at 3 to ≤5 years and 1.23 (1.12-1.36) at more than 5 years. the study reports duration bands, not a single 'year five' point estimate, so 25% sits between the two bands. [1]
the 25% figure applies to stimulant usersmisattributedthe 1.27 and 1.23 figures pool every adhd medication, atomoxetine included. the drug-level results are a bit lower: methylphenidate 1.20 (1.10-1.31) at 3 to 5 years and 1.19 (1.08-1.31) after 5 years, and lisdexamfetamine 1.23 (1.05-1.44) at 2 to 3 years but 1.17 (0.98-1.40, not significant) after 3 years. the paper does say stimulant use was linked to higher risk, so the direction holds. the label on the number is what's off. [1]
the comparison group was people not on adhd medicationsconfirmedthe reference group was people with adhd who had no adhd medication dispensed during follow-up. it was not the general population, which takes adhd itself out of the comparison. [1]
popular framing: this means stimulants cause heart attacks and strokesmisattributedthe extra risk sat in hypertension (3 to 5 years: 1.72; more than 5 years: 1.80) and arterial disease (3 to 5 years: 1.65). no significant association was found for ischemic heart disease, cerebrovascular disease or arrhythmias. the authors write that, because the study is observational, 'we could not prove causality.' [1]

both directions

for the speaker: the size and timing match the paper. odds rose with cumulative use: 1.09 at 1 to 2 years, 1.15 at 2 to 3 years and 1.27 at 3 to 5 years, about 4% per added year of use (aor 1.04, 95% ci 1.03-1.05). the paper itself says stimulant use was associated with increased risk. methylphenidate on its own still showed about 20% higher odds after 3 or more years, so a speaker summarizing the stimulant finding is not far off. comparing people with adhd to other people with adhd, rather than to the general population, also makes the comparison fairer than many in this literature.

against: the 25% is the all-medication figure, not a stimulant-only one. the stimulant-specific numbers are lower, around 17-23%, and the longer-duration lisdexamfetamine estimate was not statistically significant. "cardiovascular risk" also sounds like heart attack and stroke, but the excess was in hypertension and arterial disease, with no significant signal for ischemic heart disease, stroke or arrhythmia. these are relative odds from an observational design, and the paper gives no absolute risk. a 25% relative rise on a low baseline is a much smaller absolute change than the headline suggests, especially for children and young adults.

what this cannot say

the study is observational, and its authors say it cannot prove causality. adhd severity, lifestyle, other psychiatric medications and adherence could all confound or blur the link. there was no sibling comparison. median follow-up was 4.1 years, so estimates past five years rest on fewer people. people with existing cardiovascular disease were excluded, so the results say nothing about them. we read the published article and its open-access copy, not the supplementary tables, so our drug-level figures come only from what the main text reports. we have not heard the episode's surrounding context and are checking only the quoted sentence.

the medication pages behind this check

sources, each one fetched and read

  1. same article, open-access full text on PubMed Central, PMC10851097 What we read there: 'each 1-year increase of ADHD medication use was associated with a 4% increased risk of CVD (AOR, 1.04 [95% CI, 1.03-1.05])'. the reference group was people with adhd with no medication use. 'increased risk was also associated with stimulant medication use.' lisdexamfetamine aor was 1.23 at 2 to 3 years and 1.17 (0.98-1.40) after 3 years. arterial disease aor was 1.65 at 3 to 5 years. no significant association with arrhythmias, ischemic heart disease or cerebrovascular disease. median follow-up was 4.1 years. Fetched 2026-10-26 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC10851097/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam